These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 17391570)

  • 1. Economic outcomes and levers: impacts for individuals and society.
    Knapp M
    Int Psychogeriatr; 2007 Jun; 19(3):483-95. PubMed ID: 17391570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Psychogeriatric Association consensus statement on defining and measuring treatment benefits in dementia.
    Katona C; Livingston G; Cooper C; Ames D; Brodaty H; Chiu E
    Int Psychogeriatr; 2007 Jun; 19(3):345-54. PubMed ID: 17386120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic outcomes--friend or foe?
    Wimo A
    Int Psychogeriatr; 2007 Jun; 19(3):497-507. PubMed ID: 17346367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing health economic outcome in Alzheimer's disease clinical trials.
    Jonsson L
    J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health economics and health policy issues in Alzheimer's disease.
    Rapp T
    J Nutr Health Aging; 2010 Oct; 14(8):630-2. PubMed ID: 20922338
    [No Abstract]   [Full Text] [Related]  

  • 6. Social costs of expanding access to evidence-based supported employment: concepts and interpretive review of evidence.
    Salkever D
    Psychiatr Serv; 2013 Feb; 64(2):111-9. PubMed ID: 23117344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issues in the economic evaluation of treatment for dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
    Winblad B; Hill S; Beermann B; Post SG; Wimo A
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 3():39-45. PubMed ID: 9305515
    [No Abstract]   [Full Text] [Related]  

  • 8. IPECAD5--Fifth International Pharmaco-Economic Conference on Alzheimer's Disease.
    Gustavsson A; Jonsson L; Fillit H; Johansson G; Wimo A; Winblad B
    J Nutr Health Aging; 2010 May; 14(5):358-60. PubMed ID: 20424802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
    Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
    Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economics of Alzheimer disease.
    Leung GM; Yeung RY; Chi I; Chu LW
    Dement Geriatr Cogn Disord; 2003; 15(1):34-43. PubMed ID: 12457077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Contribution of economic evaluation and budget impact analysis to public decision in health: the example of breast cancer].
    Perrier L; Philip T
    Bull Cancer; 2010 Mar; 97(3):397-402. PubMed ID: 20159674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.
    Small GW; Rabins PV; Barry PP; Buckholtz NS; DeKosky ST; Ferris SH; Finkel SI; Gwyther LP; Khachaturian ZS; Lebowitz BD; McRae TD; Morris JC; Oakley F; Schneider LS; Streim JE; Sunderland T; Teri LA; Tune LE
    JAMA; 1997 Oct 22-29; 278(16):1363-71. PubMed ID: 9343469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of implementation strategies in health care.
    Hoomans T; Severens JL
    Implement Sci; 2014 Dec; 9():168. PubMed ID: 25518730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mental health care system optimization from a health-economics perspective: where to sow and where to reap?
    Lokkerbol J; Weehuizen R; Mavranezouli I; Mihalopoulos C; Smit F
    J Ment Health Policy Econ; 2014 Jun; 17(2):51-60. PubMed ID: 25153093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic research on Alzheimer disease: a review of the literature.
    Ernst RL; Hay JW
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 6():135-45. PubMed ID: 9437458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cost-utility analysis; uncertainties restrict applicability].
    de Neeling JN
    Ned Tijdschr Geneeskd; 2004 May; 148(22):1106-10. PubMed ID: 15198066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.